Innovation: Intelligent bacteria demonstrate high efficacy in the treatment of widespread disease irritable bowel syndrome with typical symptoms of recurrent diarrhoea, abdominal pain, bloating and constipation

New therapy with unique bacterial strain B. bifidum HI-MIMBb75 promises help for approximately 80 million Europeans suffering from irritable bowel syndrome1 - World's largest clinical OTC irritable bowel syndrome trial investigating the efficacy of this particular strain published in the renowned medical journal The Lancet Gastroenterology & Hepatology2 - Results show significant efficacy for all predominant irritable bowel syndrome symptoms and all subtypes while simultaneously improving patients’ quality of life2 (Gräfelfing/Munich, Germany) The world's largest OTC irritable bowel syndrome (IBS) trial comes up with remarkable results, which were recently published in the renowned medical journal The Lancet Gastroenterology & Hepatology. For the first time, leading German scientists around Prof. Dr. Peter Layer (Israelitic Hospital Hamburg) were able to prove the significant efficacy of a heat-inactivated bacterial strain on patients with IBS. Trial results show that B. bifidum HI-M

Gastrointestinal Disorders, Free Full-Text

Irritable Bowel Syndrome with Constipation

Xia & He Publishing

Probiotics Applications in Autoimmune Diseases

Dietary fiber in irritable bowel syndrome (Review)

Irritable bowel syndrome Nature Reviews Disease Primers

Gastrointestinal Disorders, Free Full-Text

Pharmacology of the New Treatments for Lower Gastrointestinal Motility Disorders and Irritable Bowel Syndrome - Camilleri - 2012 - Clinical Pharmacology & Therapeutics - Wiley Online Library

Restriction of FODMAP in the management of bloating in irritable bowel syndrome. - Abstract - Europe PMC